Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:29 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

NCT04589832 · Arkadiusz Z. Dudek, MD · PHASE1/PHASE2 · terminated · last registry update 2023-11-22 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

Kind	Quote	Our category	Source
Stated	“This study required dose reductions to the lower dose level (Dose level -1). But this dose level (Dose level -1) was not further explored because of lack of funding.”	–	Registry record, Arkadiusz Z. Dudek, MD

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against NTRK1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

Internal portfolio and board discussions
Unpublished trial data and interim analyses
Terms of any partner or licence decision